DataMeds AI, Inc. (MEDS) shareholders
Close on Nov 17, 2026Market cap $1.96MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Hyperscale Data, Inc. | 501,204 | 9.99% | 13G (passive) | May 27, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MEDS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 20,532 | 0.67% | $63.65K | New | 0.00% |
| Geode Capital Management, LLC | 12,467 | 0.41% | $38.65K | New | 0.00% |
| Vanguard Capital Management LLC | 11,085 | 0.36% | $34.36K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 6,191 | 0.20% | $19.19K | New | 0.00% |
| Barclays PLC | 723 | 0.02% | $2.24K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 678 | 0.02% | $2.10K | New | 0.00% |
| Fortitude Family Office, LLC | 118 | 0.00% | $366 | New | 0.00% |
| Integrated Wealth Concepts LLC | 25 | 0.00% | $78 | New | 0.00% |
| Global Retirement Partners, LLC | 2 | 0.00% | $6 | New | 0.00% |
| Danske Bank A/S | 1 | 0.00% | $3 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10 | 0M | 1.7% | 10 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
6 funds held MEDS in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MEDS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 9,385 | 0.31% | $32.10K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 9,059 | 0.30% | $28.08K | 0.00% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,026 | 0.07% | $6.28K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 1,507 | 0.05% | $5.15K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 947 | 0.03% | $3.24K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 607 | 0.02% | $2.08K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Prashant Patel | Chief Executive Officer, Director | 9,354,365 | 305.51% | Jun 25, 2026 |
| Srinivas Kalla | Chief Information Officer | 293,333 | 9.58% | Apr 24, 2025 |
| Mark DiSiena | Chief Financial Officer | – | – | Apr 23, 2025 |
| Brian Norton | Chief Executive Officer | 11,524,308 | 376.38% | Mar 25, 2025 |
| Nikul Panchal | Chief Pharmacy Officer | 375,761 | 12.27% | Mar 25, 2025 |
| Shafaat Pirani | Chief Clinical Officer | 102,080 | 3.33% | Mar 25, 2025 |
| Surendra K. Ajjarapu | Director | 15,445,447 | 504.44% | Jun 25, 2026 |
| Gary L. Herman | Director | – | – | Apr 10, 2026 |
| Eric Michael Sherb | Director | – | – | Apr 9, 2026 |
| Marlene Velez | Director | – | – | Apr 2, 2026 |
| Howard A. Doss | Director | – | – | Oct 24, 2025 |
| Donald G. Fell | Director | – | – | Oct 21, 2025 |
| Steven Dale Lee | Director | – | – | Oct 14, 2025 |
| Michael L. Peterson | Director | 200,000 | 6.53% | Jul 8, 2025 |
| Donald William Anderson | Director | 244,720 | 7.99% | Mar 25, 2025 |
| Rebecca M. Shanahan | Director | 244,720 | 7.99% | Mar 25, 2025 |
| Sajid Syed | Director | 244,720 | 7.99% | Mar 25, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Prashant Patel Chief Executive Officer, Director | Jun 22, 2026 | Option exercise | +100,000 | $0.01 | $1.00K | 282,365 |
| Surendra K. Ajjarapu Director | Jun 22, 2026 | Option exercise | +100,000 | $0.01 | $1.00K | 257,645 |
| Surendra K. Ajjarapu Director | Mar 31, 2026 | Award | +5,000,000 | $0.20 | $1.00M | 7,882,247 |
| Prashant Patel Chief Executive Officer, Director | Mar 31, 2026 | Award | +5,000,000 | $0.20 | $1.00M | 9,118,247 |
| Surendra K. Ajjarapu Director | Mar 31, 2026 | Award | +5,000,000 | $0.20 | $1.00M | 7,882,247 |
| Prashant Patel Chief Executive Officer, Director | Mar 31, 2026 | Award | +5,000,000 | $0.20 | $1.00M | 9,118,247 |
| Michael L. Peterson Director | Jul 2, 2025 | Award | −200,000 | $0.90 | $180.00K | 200,000 |
| Surendra K. Ajjarapu Director | Mar 21, 2025 | Award | +600,000 | – | – | 4,463,200 |
| Surendra K. Ajjarapu Director | Mar 21, 2025 | Award | +600,000 | – | – | 3,100,000 |
| Surendra K. Ajjarapu Director | Mar 21, 2025 | Award | +2,882,247 | – | – | 1,822,247 |
| Prashant Patel Chief Strategy Officer, Director | Mar 21, 2025 | Award | +1,882,247 | – | – | 4,118,247 |
| Prashant Patel Chief Strategy Officer, Director | Mar 21, 2025 | Award | +1,500,000 | – | – | 1,500,000 |
| Prashant Patel Chief Strategy Officer, Director | Mar 21, 2025 | Award | +700,000 | – | – | 700,000 |
| Shafaat Pirani Chief Clinical Officer | Mar 21, 2025 | Award | +35,000 | – | – | 102,080 |
| Donald William Anderson Director | Mar 21, 2025 | Award | +200,000 | – | – | 244,720 |
| Rebecca M. Shanahan Director | Mar 21, 2025 | Award | +200,000 | – | – | 244,720 |
| Brian Norton Chief Executive Officer | Mar 21, 2025 | Award | +9,000,000 | – | – | 9,044,720 |
| Sajid Syed Director | Mar 21, 2025 | Award | +200,000 | – | – | 244,720 |
| Nikul Panchal Chief Pharmacy Officer | Mar 21, 2025 | Award | +90,000 | – | – | 90,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of DataMeds AI's stock actually held short. Settlement fails (shares not delivered on time) peaked at 281,963 shares on Sep 16, 2026 over the last 90 days.
See a number that looks wrong?